M2I1

M2I1 is a small molecule inhibitor designed to disrupt the protein-protein interaction between Mitotic Arrest Deficient 2 Like 1 (MAD2L1) and Cell Division Cycle 20 (CDC20). This interaction is a critical component of the spindle assembly checkpoint (SAC), a surveillance mechanism that ensures proper chromosome segregation during mitosis by preventing the premature activation of the anaphase-promoting complex/cyclosome (APC/C). By inhibiting the formation of the MAD2-CDC20 complex, M2I1 causes cells to bypass the SAC, leading to premature mitotic exit, chromosomal instability, and subsequent apoptosis. Research, particularly at the University of Texas MD Anderson Cancer Center, has identified MAD2L1 as a potential therapeutic target in multiple myeloma, where its overexpression correlates with poor prognosis. Preclinical studies have demonstrated that M2I1 treatment results in dose- and time-dependent inhibition of myeloma cell proliferation and viability.

Other names

Mad2 Inhibitor-1Mad-2 Inhibitor-1Mad 2 Inhibitor-1MAD2-CDC20 inhibitorMAD-2-CDC20 inhibitorMAD 2-CDC20 inhibitor